Pfizer Inc.
27.78USD
-0.0100 (-0.04%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 91.8B | 50.9B | 63.6B | 62.6B | 62.2B | 59.8B |
| Q1 | 25.7B | 18.5B | 14.9B | 13.7B | 14.5B | — |
| Q2 | 27.7B | 13.0B | 13.3B | 14.7B | 15.0B | — |
| Q3 | 22.6B | 13.5B | 17.7B | 16.7B | 15.9B | — |
| Q4 | 15.8B* | 5.9B* | 17.8B* | 17.6B* | 16.9B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 5.47 | .370 | 1.41 | 1.36 | 2.98 | 2.90 |
| Q1 | 1.37 | .970 | .550 | .520 | .470 | — |
| Q2 | 1.73 | .410 | .010 | .510 | -.040 | — |
| Q3 | 1.51 | -.420 | .780 | .620 | .759 | — |
| Q4 | .871* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.590* |
| .072* |
| -.288* |
| .708 |
| — |